Intrinsiqq
CONMED Corporation logo

CONMED Corporation Quality Score

CNMD

Compare
Quality68

Valuation remains strong (avg 90/100), but business quality is pulling the composite down (avg 38/100).

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
80/100
22.6x

20–25x range, moderate premium

Cash Flow Multiple
100/100
9.2x

Under 20x cash flow, well covered

Revenue Growth
70/100
7.4%

5–10% CAGR, steady but not exceptional

Cash Flow Growth
100/100
135.3%

Above 10% CAGR, strong compounder

Business Quality & Capital Allocation

Share Dilution
60/100
0.3%

Mild dilution under 2%

Margin Trend
90/100
+2.1pp

Expanded 1–3pp, steady progress

Capital Structure
0/100
$769M

Net debt/FCF of 5.1x, high leverage

2022
$29.0M
$1.07B
2023
$24.0M
$994M
2024
$24.0M
$949M
2025
$41.0M
$889M
TTM
$48.0M
$817M
CashDebt
Return on Capital
0/100
5.0%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

CONMED (CNMD) quality: score, margins and returns

CONMED (CNMD) scores 68/100 on Intrinsiqq's quality score (a solid business), a weighted blend of 8 metrics each scored 0 to 100, on 8.8% operating margins and 5.0% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is CONMED (CNMD) a high-quality business?+

CONMED scores 68 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which rates it a solid business on these measures. Recent figures include a 8.8% operating margin and a 5.0% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does CONMED's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from CNMD's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where CONMED scores well and where it falls behind.

What is CONMED's return on invested capital (ROIC)?+

CONMED earns about 5.0% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to CNMD's margins and growth on this scorecard to judge durability.

How profitable is CONMED?+

CONMED runs an operating margin of about 8.8% and a net margin of about 4.5%. Revenue has grown at roughly 9.8% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 26 Oct 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 29 Oct 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Electromedical & Electrotherapeutic Apparatus · Pick stocks to compare with CNMD

CompareIntrinsic value
LIVNLivaNova PLC
$90.73-1.46%65
MASIMasimo Corporation
No recent price62
ITGRInteger Holdings Corporation
$126.97+0.21%42
TMDXTransMedics Group Inc.
$85.25-9.33%53
INMDInMode Ltd.
$12.42-2.20%49
AXGNAxogen Inc.
$55.75-1.06%61
HAEHaemonetics Corporation
$120.16-0.17%53
PENPenumbra Inc.
$319.12-0.28%72

Held by ETFs

CNMD is in 71 US ETFs. The largest of them, with CNMD's weight in each:

Spot a number that looks wrong? Check it in CNMD's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing CNMD

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.